이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Med Life 관리

관리 기준 확인 2/4

Med Life's CEO는 Mihail Marcu, Dec2016 에 임명되었습니다 의 임기는 7.5 년입니다. 는 RON 445.01M 가치에 해당하는 회사 주식의 14.78% 직접 소유합니다. 445.01M. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 7.5 년입니다.

주요 정보

Mihail Marcu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.6yrs
CEO 소유권	14.8%
경영진 평균 재임 기간	6.8yrs
이사회 평균 재임 기간	7.6yrs

최근 관리 업데이트

Recent updates

CEO

Mihail Marcu (54 yo)

7.6yrs

테뉴어

Mr. Mihail Marcu serves as Chief Executive Officer at S.C. Med Life S.A. since December 2016. Mr. Marcu served as the Chief Executive Officer of MedLife between January 2004 until August 2006 and vice pres...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mihail Marcu	Chairman & CEO	7.6yrs	데이터 없음	14.78% RON 461.5m
Alina Irinoiu	CFO & Investor Relations Manager	1.8yrs	데이터 없음	데이터 없음
Nicolae Marcu	Chief Healthcare & Operations Officer and Director	no data	데이터 없음	10.42% RON 325.4m
Vera Firu	Accounting & Tax Director	no data	데이터 없음	데이터 없음
Radu Petrescu	Human Resources Director	6.8yrs	데이터 없음	데이터 없음
Mirela Dogaru	Commercial Director	no data	데이터 없음	데이터 없음
Dorin Preda	Chief Finance	no data	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: M 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mihail Marcu	Chairman & CEO	17.9yrs	데이터 없음	14.78% RON 461.5m
Nicolae Marcu	Chief Healthcare & Operations Officer and Director	7.6yrs	데이터 없음	10.42% RON 325.4m
Dorin Preda	Chief Finance	16.5yrs	데이터 없음	데이터 없음
Ovidiu Fer	Independent Director	3.6yrs	데이터 없음	데이터 없음
Ana Mihaescu	Independent Director	6.8yrs	데이터 없음	데이터 없음
Dimitrie Pelinescu-Onciul	Director	16.5yrs	데이터 없음	데이터 없음
Voicu Cheta	Independent Director	3.6yrs	데이터 없음	데이터 없음

7.6yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: M 의 이사회는 경험(평균 재직 기간 7.5 년)으로 간주됩니다.

Med Life 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Med Life S.A., Annual General Meeting, Apr 27, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Now 28% undervalued

Now 28% undervalued

Now 22% undervalued

The Market Lifts Med Life S.A. (BVB:M) Shares 25% But It Can Do More

Full year 2023 earnings released: EPS: RON0.007 (vs RON0.061 in FY 2022)

Is Med Life (BVB:M) A Risky Investment?

Full year 2023 earnings released: EPS: RON0.007 (vs RON0.061 in FY 2022)

Full year 2023 earnings released

Med Life S.A. to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Price target decreased by 7.3% to RON20.21

Returns On Capital Signal Tricky Times Ahead For Med Life (BVB:M)

First quarter 2023 earnings released

Full year 2022 earnings released: EPS: RON0.30 (vs RON0.77 in FY 2021)

Price target increased by 31% to RON20.45

Med Life S.A., Annual General Meeting, Apr 27, 2023

Med Life S.A. (BVB:M) acquired 99.76% stake in Muntenia Medical Competences SA.

Is Med Life (BVB:M) A Risky Investment?

Med Life (BVB:M) Hasn't Managed To Accelerate Its Returns

Third quarter 2022 earnings released

Less than half of directors are independent

Third quarter 2022 earnings released

Med Life S.A. (BVB:M) completed the acquisition of 80% stake in Medici's Group.

We Think Med Life (BVB:M) Is Taking Some Risk With Its Debt

Price target decreased to RON19.50

Med Life S.A. (BVB:M) acquired majority stake in SanoPass SRL.

Med Life S.A. (BVB:M) acquired majority stake in SanoPass SRL.

Second quarter 2022 earnings released

Med Life S.A. (BVB:M) acquired 60% stake in Opticristal - ophthalmological clinic.

Med Life S.A. (BVB:M) agreed to acquire SWEAT CONCEPT ONE.

Med Life S.A. (BVB : M) acquired Medicris Oradea Group.

Med Life S.A. (BVB:M) entered into an agreement to acquire 80% stake in Medici's Group.

Price target increased to RON26.13

Returns Are Gaining Momentum At Med Life (BVB:M)

Less than half of directors are independent

Med Life S.A. (BVB:M) acquired 60% interest in Pro Life Clinics.

Investor sentiment deteriorated over the past week

Is There An Opportunity With Med Life S.A.'s (BVB:M) 49% Undervaluation?

Med Life S.A. (BVB:M) completed the acquisition of 50% stake in Neolife Medical Center Romania.

Med Life (BVB:M) Shareholders Will Want The ROCE Trajectory To Continue

Third quarter 2021 earnings released

Price target increased to RON17.40

Price target increased to RON14.65

Does Med Life (BVB:M) Have A Healthy Balance Sheet?

Med Life's (BVB:M) Returns On Capital Are Heading Higher

Med Life S.A. (BVB:M) acquired remaining 10% stakes in Clinica Medicala Panduri.

Med Life S.A. (BVB:M) acquired the remaining 10% stake in Centrul Medical Panduri S.A.

Here's Why We Think Med Life (BVB:M) Is Well Worth Watching

Is Now An Opportune Moment To Examine Med Life S.A. (BVB:M)?

Is There An Opportunity With Med Life S.A.'s (BVB:M) 24% Undervaluation?

Med Life S.A. (BVB:M) acquired 60% stake in Medica Sibiu.

Update: Med Life (BVB:M) Stock Gained 98% In The Last Year

Should We Be Excited About The Trends Of Returns At Med Life (BVB:M)?

Revenue and earnings beat expectations

Full year 2020 earnings released

Should You Be Impressed By Med Life S.A.'s (BVB:M) ROE?

Med Life (BVB:M) Seems To Use Debt Quite Sensibly

Price target raised to RON8.47

Is It Too Late To Consider Buying Med Life S.A. (BVB:M)?

Do Med Life's (BVB:M) Earnings Warrant Your Attention?

New 90-day high: RON11.20

Is Med Life S.A. (BVB:M) Trading At A 22% Discount?

Investor sentiment improved over the past week

Med Life S.A. (BVB:M) agreed to acquire 75% stake in Pharmachem Distributie SRL on December 15, 2020.

New 90-day high: RON51.60

Did You Miss Med Life's (BVB:M) 49% Share Price Gain?

The Trends At Med Life (BVB:M) That You Should Know About

Med Life S.A. (BVB:M) acquired Veridia Medical Center.

New 90-day high: RON48.20

Market bids up stock over the past week

New 90-day high: RON39.60